Pfizer's (NYSE:PFE) stock is up by 4.7% over the past three months. Given that the markets usually pay for the long-term ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...

Dividend-paying stocks can really boost an individual investor's portfolio. If you're in the market for some no-brainer ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

US stocks extended losses on Wednesday as weakness in tech megacaps outweighed solid economic data and mixed results from ...

Let's discuss how the drugs in these two non-oncology segments are expected to have performed in the third quarter. In ...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, ...